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Lamivudine plus a boosted-protease inhibitor as simplification
strategy in HIV-infected patients with toxicity to nucleoside
analogues
Casado, J; De la Calle, C; Del Palacio, M; Ban ˜on, S; Pe ´rez Elı ´as, M; Moreno, A and Moreno, S
Ramon y Cajal Hospital, Infectious Diseases, Madrid, Spain.
Purpose of the study
Dual therapy with lamivudine plus a PI boosted with ritonavir (PI/r) could be an alternative to standard triple therapy or PI/r
monotherapy as a simplification strategy in patients with toxicity to nucleoside analogues (NA).
Methods
Retrospective cohort study of 44 HIV-infected patients on suppressive HAART, with no chronic HBV, who simplified to this dual
therapy since 2008. Virological and immunological outcome, lipids and renal changes were evaluated.
Summary of results
Mean age was 50 years (38-70), 66% were male, and the median time of HIV infection was 18.6 years. The median nadir
CD4 count was 150 cells/ml (2407). At inclusion, patients were receiving therapy with lamivudine plus atazanavir/r in 5
cases, lopinavir/r in 12, and darunavir/r in 27, and they had an HIV RNA levelB50 copies/ml for a median time of 794 days
(1292344, 90%  6 months). The NA discontinued was tenofovir (27), didanosine (12), AZT (3), and d4T (2). The reasons for
changing were toxicity in 76% of cases, especially renal impairment.They had received a mean of 8 regimens before (220), and
55% were in CDC-stage C. In 11 cases, history of resistance was available (to NA in 7 cases, including the 210W mutation in four).
The mutations 184V was not observed, but four patients (9%) had a previous failure to therapy including 3tC. Mutations in the
protease gene were observed in 8 patients (2 to 7 mutations, the most frequent 77I and 93L), without resistance to the current
PI/r. During 62.8 patient-years of follow-up (median, 802 days), only 2 patients failed (4.5%), due to incomplete adherence, at 27
and 141 days. Of note, these two patients had no previous failed with 3tC or PI. Overall, CD4 count increased for 55 cells/ml.
No new adverse events were observed, but total cholesterol (from 180 to 246 mg/dl, p0.007) and triglycerides (from 166 to
195, p0.01) increased during the first 24 weeks with improvement at 48 weeks. On the other hand, estimated glomerular
filtration rate improved during follow up (from 74.2 ml/min to 83.08 ml/min after 48 weeks, p0.1).
Conclusions
Dual therapy with lamivudine plus a boosted PI is safe and effective as simplification strategy in patients with toxicity to NA.This
combination could be an alternative to mono or triple therapy in hard to treat patients, although an initial increase in lipid
parameters could be observed.
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